PRInnovation GmbH, a subsidiary of SPRIND, is working on the clinical development of a drug candidate against Alzheimer’s dementia with an innovative mechanism of action. We are cooperating closely with the company Priavoid. Currently we are running the Clinical Phase 2 PRImus-AD study. The ongoing progress of the study requires additional support for our ambitious […]